Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Von Willebrand Factor Concentrate in Adult Patients During ECMO
NCT03613584Phase 2Unknown
- Sponsor
- Tirol Kliniken
- Start
- Apr 2018
- Primary completion
- Mar 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vonicog alfa in acquired von Willebrand syndrome (AVWS) (2 arms), sponsored by Tirol Kliniken. Primary endpoint: Transfusion requirement of packed red blood cells (PRBC) at 24 hours. Status: unknown.
02
Drugs
vonicog alfa
03
Conditions
acquired von Willebrand syndrome (AVWS)
Beyond the preview
Go deeper on NCT03613584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03613584.